Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

Hoth Therapeutics has received approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human Phase 2a clinical trial of HT-001. This milestone marks multiple sites hosting the trial, as Washington University of St Louis previously approved it as well. The randomized, placebo-controlled, parallel Phase 2a dose-ranging study aim..